SEARCH

SEARCH BY CITATION

References

  • 1
    Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217223.
  • 2
    Centers for Disease Control and Prevention. QuickStats: percentag of persons aged ≥20 years with hypertension, by race/ethnicity—United States, 1999–2002. MMWR. 2005;54:826.
  • 3
    Cheung BMY, Ong KL, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey 2001–2002. J Clin Hypertens (Greenwich). 2006;8:9398.
  • 4
    Ong KL, Cheung BMY, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension. 2007;49:6975.
  • 5
    Moser M, Franklin SF. Hypertension management: results of a new national survey for the Hypertension Education Foundation: Harris Interactive. J Clin Hypertens (Greenwich). 2007;9:316323.
  • 6
    Centers for Disease Control and Prevention (CDC). Prevalence of actions to control high blood pressure—20 states, 2005. MMWR. 2007;56(17):420423.
  • 7
    Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43:1017.
  • 8
    Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:19031913.
  • 9
    Basile J, Houston M, Ferrario C. Incremental risk-factor reduction improves overall cardiovascular benefit: is it time to abandon the silos? J Clin Hypertens (Greenwich). 2006;8:686688.
  • 10
    Düsing R. Overcoming barriers to effective blood pressure control in patients with hypertension. Curr Med Res Opin. 2006;22:15451553.
  • 11
    Rosamond W, Flegal K, Friday G, et al, for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and the Stroke Statistics Subcommittee. Circulation. 2007;115:e69e171.
  • 12
    Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 2000;356:19551964.
  • 13
    Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:15271535.
  • 14
    Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:12061252.
  • 15
    Staessen JA, Li Y, Thijs L, et al. Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. Hypertens Res. 2005;28:385407.
  • 16
    Basile JN, Chrysant S. The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy. J Hum Hypertens. 2006;20:169175.
  • 17
    Hansson L, Zanchetti A, Carruthers SG, et al, for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:17551762.
  • 18
    UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703713.
  • 19
    Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:20222031.
  • 20
    Staessen JA, Thijs L, Fagard R, et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe trial. J Hypertens. 2004;22:847857.
  • 21
    Lithell H, Hansson L, Skoog I, et al, for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): outcomes in patients not receiving add-on therapy after randomization. J Hypertens. 2004;22:16051612.
  • 22
    Dahlöf B, Sever PS, Poulter NR, et al, for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflume-thiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895906.
  • 23
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:29812997.
  • 24
    Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet. 2004;363:20492051.
  • 25
    Lithell H, Hansson L, Skoog I, et al, for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875886.
  • 26
    Weycker D, Edelsberg J, Vincze G, et al. Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine. J Hum Hypertens. 2007;21:374380.
  • 27
    The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. Eur Heart J. 2007;28:14621536.
  • 28
    Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:27612788.
  • 29
    Okonofua EC, Simpson KN, Jesri A, et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47:345351.
  • 30
    Neutel JM, Smith DHG. Improving patient compliance: a major goal in the management of hypertension. J Clin Hypertens (Greenwich). 2003;5:127132.
  • 31
    Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002;62:443462.
  • 32
    Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and strokes: a new preventive strategy. Health Technol Assess. 2003;7:194.
  • 33
    Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:14271434.
  • 34
    Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713719.
  • 35
    Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm. 2007;64:12791283.
  • 36
    Elliot WJ. Is fixed combination therapy appropriate for initial hypertension treatment? Curr Hypertens Rep. 2002;4:278285.
  • 37
    Bizien MD, Jue SG, Panning C, et al. Blood pressure control and factors predicting control in a treatment-compliant male veteran population. Pharmacotherapy. 2004;24:179187.
  • 38
    Philipp T, Glazer R, Wernsing M, et al. Dual calcium channel and angiotensin II receptor blockade is superior to amlodipine or valsartan alone for optimal hypertension control. J Clin Hypertens (Greenwich). 2007;9(suppl A):A39. Abstract P-83.
  • 39
    Scholze J, Bida M, Hansen A, et al. Initiation of hypertension treatment with a fixed-dose combination or its mono-components—does it really matter? Int J Clin Pract. 2006;60:265274.
  • 40
    Rubio-Guerra AF, Arceo-Navarro A, Lozano-Nuevo JJ, et al. Efficacy of a fixed-dose combination of trandolapril-verapamil in patients with stage 2 hypertension inadequately controlled by monotherapy. Clin Drug Investig. 2005;25:445451.
  • 41
    Jamerson KA, Bakris GL, Wun CC, et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens. 2004;17:793801.
  • 42
    Jamerson K, Bakris GL, Dahlöf B, et al, for the ACCOMPLISH Investigators. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007;16:8086.